Clinical Trial Update: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for ProAgio in pancreatic ductal adenocarcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ProAgio

Snippet

Sponsor: ProDa BioTech, LLC | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Status: RECRUITING